Drug Profile

GBV 006

Alternative Names: GBV-006

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stanford University School of Medicine
Developer Globavir Biosciences
Class Antivirals
Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Phase II COVID 2019 infections
No development reported Dengue; Hantavirus infections; Lassa fever; Marburg virus disease
Discontinued Ebola virus infections; Respiratory syncytial virus infections

28 May 2024 No recent reports of development identified for preclinical development in Hantavirus-infections in USA
28 May 2024 No recent reports of development identified for preclinical development in Lassa-fever in USA
28 May 2024 No recent reports of development identified for preclinical development in Marburg virus disease in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com